Rubius Therapeutics, a preclinical biotech developing novel therapies based on red blood cells, raised $241 million by offering 10.5 million shares at $23, above the $20 to $22 range. The company had originally planned to raise $200 million by selling 9.5 million shares at $21. At pricing, the Cambridge, MA-based company will command a fully diluted market value of $2.0 billion and an enterprise value of $1.6 billion. Rubius Therapeutics plans to list on the Nasdaq under the symbol RUBY. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as lead managers on the deal.
